NurOwn® will be made available for ALS patients who completed all Phase 3 clinical trial assessments and meet specific eligibility criteria NEW YORK, Dec. 14, 2020 /PRNewswire/ -- BrainStorm Cell ...
A conference call and webcast will be held Tomorrow, April 9, at 8:00 a.m. Eastern Time NEW YORK, April 8, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of ...
NEW YORK, June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival data ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. There’s bi-partisan support in North ...
NEW YORK, Oct. 28, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of ...
The webinar will take place on July 8, 2020 at 8:15 AM ET. The presentation will be followed by a question-and-answer session with Professors Scheltens and Dubois and with BrainStorm management.
A University of Oklahoma writing program has released its third annual journal of essays, written entirely by students. “Brainstorm” is produced each year by OU’s Edith Kinney Gaylord Expository ...
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results